New combo attack on leukemia shows promise in early trial

NCT ID NCT05306301

Ongoing Disease control Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding the targeted drug ponatinib to standard chemotherapy can improve outcomes for adults with a specific, high-risk type of acute lymphoblastic leukemia called BCR/ABL1-like ALL. The study enrolls 32 patients aged 18-65 who have not yet been treated. The main goal is to see how many achieve a deep remission (MRD negativity) after three cycles of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ponatinib (a targeted drug that blocks cancer growth signals)
What this could lead to: If successful, this could offer a more effective first-line treatment for a hard-to-treat form of acute lymphoblastic leukemia, potentially improving remission rates.
What could go wrong: This is a small Phase 2 study (32 people) with no control group, so results may not be definitive. Ponatinib can cause serious side effects like blood clots, pancreatitis, and liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCR::ABL1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like lymphoblastic leukemia, acute, with lymphomatous features Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY LEUKEMIA, ACUTE LYMPHOBLASTIC

Contacts and locations

Locations

Dipartimento di Medicina Traslazionale e di Precisione - Ematologia

Roma, Italy
Ematologi Presidio Ospedaliero Guglielmo da Saliceto

Piacenza, Italy
Ematologia AO Ospedali Riuniti Villa Sofia Cervello

Palermo, Italy
Ematologia AOU Careggi

Florence, Italy
Ematologia AOU Federico II

Naples, Italy
Ematologia AOU Maggiore della Carità

Novara, Italy
Ematologia AOU Policlinico Tor Vergata

Roma, Italy
Ematologia AOU Policlinico Vittorio Emanuele-Ferrarotto

Catania, Italy
Ematologia AOU S.ORSOLA-MALPIGHI

Bologna, Italy
Ematologia AOU Senese

Siena, Italy
Ematologia ASST Papa Giovanni XXIII

Bergamo, Italy
Ematologia ASST Spedali Civili

Brescia, Italy
Ematologia Fondazione Policlinico San Matteo

Pavia, Italy
Ematologia Ospedale Maggiore Policlinico

Milan, Italy
Ematologia Ospedale Mauriziano

Torino, Italy
Ematologia Ospedale S.Giovanni Battista Molinette

Torino, Italy
Ematologia Ospedale V.Fazzi

Lecce, Italy
Ematologia Ospedale dell'Angelo

Mestre, Italy
Ematologia Policlinico A.Gemelli

Roma, Italy
Ematologia Policlinico G.B. Rossi

Verona, Italy
Ematologia Presidio Ospedaliero Infermi

Rimini, Italy
Ematologia Presidio Ospedaliero Spirito Santo

Pescara, Italy
Ematologia Presidio Ospedaliero Tortora

Pagani, SA, Italy
Ematologia con Unità di Trapianto

Avellino, AV, 83100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.